These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7902766)

  • 1. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial.
    Duinkerke SJ; Botter PA; Jansen AA; van Dongen PA; van Haaften AJ; Boom AJ; van Laarhoven JH; Busard HL
    Br J Psychiatry; 1993 Oct; 163():451-5. PubMed ID: 7902766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Akhondzadeh S; Malek-Hosseini M; Ghoreishi A; Raznahan M; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1879-83. PubMed ID: 18801405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms.
    Abi-Saab W; Seibyl JP; D'Souza DC; Karper LP; Gueorgueva R; Abi-Dargham A; Wong ML; Rajhans S; Erdos JP; Heninger GR; Charney DS; Krystal JH
    Psychopharmacology (Berl); 2002 Jun; 162(1):55-62. PubMed ID: 12107618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating negative symptoms.
    Bailey P; Duval F; Macher JP
    Br J Psychiatry; 1994 May; 164(5):699-700. PubMed ID: 7921730
    [No Abstract]   [Full Text] [Related]  

  • 5. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia.
    Wiesel FA; Nordström AL; Farde L; Eriksson B
    Psychopharmacology (Berl); 1994 Feb; 114(1):31-8. PubMed ID: 7846205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial.
    Akhondzadeh S; Mohajari H; Reza Mohammadi M; Amini H
    BMC Psychiatry; 2003 Jun; 3():7. PubMed ID: 12816549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients.
    Allan ER; Alpert M; Sison CE; Citrome L; Laury G; Berman I
    J Clin Psychiatry; 1996 Oct; 57(10):455-9. PubMed ID: 8909331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
    Tollefson GD; Sanger TM
    Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychotropic effects of ritanserin, a selective S2 antagonist: an open study.
    Strauss WH; Klieser E
    Eur Neuropsychopharmacol; 1991 May; 1(2):101-5. PubMed ID: 1821698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
    Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
    J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
    Bersani G; Grispini A; Marini S; Pasini A; Valducci M; Ciani N
    Clin Neuropharmacol; 1990 Dec; 13(6):500-6. PubMed ID: 2125857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Kardashev A; Ratner Y; Ritsner MS
    Clin Schizophr Relat Psychoses; 2018; 12(1):31-41. PubMed ID: 26218236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind trial of carbamazepine in negative symptom schizophrenia.
    Nachshoni T; Levin Y; Levy A; Kritz A; Neumann M
    Biol Psychiatry; 1994 Jan; 35(1):22-6. PubMed ID: 7909450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
    Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM
    J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia.
    Shiloh R; Zemishlany Z; Aizenberg D; Valevski A; Bodinger L; Munitz H; Weizman A
    Int Clin Psychopharmacol; 2002 Mar; 17(2):59-64. PubMed ID: 11890187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin.
    Bersani G; Pozzi F; Marini S; Grispini A; Pasini A; Ciani N
    Acta Psychiatr Scand; 1991 Apr; 83(4):244-8. PubMed ID: 1903019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
    Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.